GlassScriptPhysician profile
Elana Godebu
NPI 1609189224
$2,930.44
in general payments reported to CMS, 2019-2025
15 companies · $705 in 2025
The $705 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2021: $40.92 · 2022: $216 · 2023: $325 · 2024: $752 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494 · Travel and Lodging: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.49 |
| Travel and Lodging | $286.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,150.62 | 2023-2025 | Urolift, Barrigel |
| Uromedica, Incorporated | $892.33 | 2019 | |
| Urogen Pharma, INC. | $204.17 | 2022-2025 | |
| Medtronic, INC. | $180.22 | 2022 | |
| Sumitomo Pharma America, INC. | $179.41 | 2023-2025 | Gemtesa, Orgovyx |
| Alnylam Pharmaceuticals INC. | $67.07 | 2024-2025 | Oxlumo |
| Olympus America INC. | $65.61 | 2023-2025 | Cysto-Nephro Videoscope, Itind System |
| Pfizer INC. | $40.33 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $29.22 | 2025 | |
| Myovant Sciences INC. | $27.55 | 2021 | |
| Ferring Pharmaceuticals INC. | $25.91 | 2025 | Adstiladrin |
| Abbvie INC. | $23.26 | 2025 | |
| Janssen Biotech, INC. | $16.41 | 2025 | Erleada |
| Boston Scientific Corporation | $14.96 | 2024 | Wavewriter Alpha Prime 16 |
| Rochester Medical Corporation | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elana Godebu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.